<DOC>
	<DOCNO>NCT00396422</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability 50 , 100 , 200 , 300 mg/day dos RWJ-445380 12 week patient plaque psoriasis</brief_summary>
	<brief_title>Study Investigate Safety , Tolerability , Absorption , Distribution , Metabolism , Elimination RWJ-445380 Administered Patients With Plaque Psoriasis</brief_title>
	<detailed_description>Trials new , first-in-class drug do ascertain safety , tolerability , absorption effect treatment psoriasis , effect biomarkers . Approximately 60 adult patient psoriasis cover least 3 percent body surface area recruit study . They randomly assign one 5 treatment arm patient equal chance receive placebo , 50 mg , 100 mg , 200 mg , 300 mg dose . Patients receive study medication blind fashion , i.e , patient , doctor study sponsor know group patient patient complete study . Patients take medication daily 12 week . The study enrol two enrollment group 30 patient , extent side effect ascertain expectation extent confirm . The investigator sponsor monitor study occurrence possible side effect . In addition screen visit , patient visit every week first month , every two week 12 week treatment . At 12 week , 2 visit consecutive day test one followup visit 4 week last dose study drug take . Medical history , physical examination , blood pressure heart rate , ECGs check periodically . Blood sample take standard laboratory test well special test drug blood level , biomarkers see whether drug might affect biological pathway antigen presentation , skin biopsy area involve involved psoriasis . The blood skin sample use see whether characteristic psoriasis change take drug . Samples also take see whether certain type immune cell affect take drug . Immunizations tetanus hepatitis A vaccines do see take drug might affect immune response agent . Patients receive RWJ-445380 , 50 , 100 , 200 , 300 mg , placebo . Patients receive oral capsule daily 12 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Diagnosis plaque psoriasis least 6 month willingness undergo tissue biopsies No current oral injectable medication psoriasis ( 30 day 3 month ) major health issue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>skin</keyword>
	<keyword>auto immune</keyword>
</DOC>